Omidubicel联合脐带血移植治疗镰状细胞病
结果显示omidubicel扩增约80倍CD34+细胞,中性粒细胞植入中位7天,双脐带血组无事件生存率85%(中位随访4年),但急性GVHD发生率较高。
要点
- Omidubicel扩增脐带血CD34+细胞约80倍,中性粒细胞植入中位7天。
- 双脐带血组无事件生存率85%(中位随访4年),单脐带血组3例1年时均存活。
- 急性GVHD发生率较高,但所有存活患者均缓解。
核心结论
- Omidubicel体外扩增脐带血可支持镰状细胞病患者植入。
- 降低GVHD发生率的策略需优化以用于镰状细胞病患者。
研究设计与样本
- 13例接受omidubicel联合未经处理的脐带血移植物,3例接受单用omidubicel移植物。
- 移植物与患者至少4/6 HLA等位基因匹配,移植中位年龄13岁。
主要发现
- Omidubicel中位CD34+扩增约80倍,中性粒细胞植入中位7天。
- 多数双脐带血受者长期植入来自未经处理的移植物,3例单用omidubicel受者中2例持续植入。
- 急性GVHD发生率较高,但所有存活患者均缓解。
- 双脐带血组无事件生存率85%(中位随访4年),单脐带血组3例移植后1年均存活。
临床怎么用
- Omidubicel扩增脐带血可作为缺乏HLA相合同胞供者的镰状细胞病患者移植选择。
- 需关注急性GVHD风险并优化GVHD预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many patients with sickle cell disease (SCD) do not have HLA-matched related donors for hematopoietic stem cell transplantation (HSCT). Unrelated cord blood (UCB) is an alternative graft option but is historically associated with high graft failure rates, with inadequate cell dose a major limitation. Omidubicel is a nicotinamide-based, ex vivo-expanded UCB product associated with rapid engraftment in adults with hematologic malignancies. We hypothesized that increasing the UCB cell dose with this strategy would lead to improved engraftment in pediatric patients undergoing myeloablative HSCT for SCD. We report the outcomes of a phase 1/2 study in 13 patients with severe SCD who received omidubicel in combination with an unmanipulated UCB graft and 3 who received a single omidubicel graft. Grafts were minimally matched with patients at 4 of 6 HLA alleles. Median age at transplant was 13 years. A median CD34+ expansion of ∼80-fold was observed in omidubicel and led to rapid neutrophil engraftment (median, 7 days). Long-term engraftment was derived from the unmanipulated graft in most of the double cord blood recipients. Two of the 3 single omidubicel recipients also had sustained engraftment. Incidence of acute graft-versus-host disease (GVHD) was high, but resolved in all surviving patients. Event-free survival in the double cord group was 85% (median follow-up 4 years). All 3 patients in the single cord group were alive at 1 year after transplantation. Ex vivo expansion of UCB with omidubicel supports engraftment in patients with SCD. This approach to decreasing the incidence of GVHD should be optimized for general use in patients with SCD. This study was registered at www.clinicaltrials.gov as #NCT01590628.
引用
- Parikh S, Brochstein JA, Galamidi E, et al. Allogeneic stem cell transplantation with omidubicel in sickle cell disease. Blood Adv. 2021. PMID: 33560399. doi:10.1182/bloodadvances.2020003248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。